Essilor® Stellest® Lenses Multicentre European Study (SLOMES) - Trial NCT06263946
Access comprehensive clinical trial information for NCT06263946 through Pure Global AI's free database. This phase not specified trial is sponsored by Essilor International and is currently Not yet recruiting. The study focuses on Myopia. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Essilor International
Timeline & Enrollment
N/A
Mar 01, 2024
Dec 30, 2026
Primary Outcome
Change in cycloplegic axial length,Change in cycloplegic autorefraction
Summary
The goal of this post-market clinical follow up Study is to demonstrate the efficacy, safety,
 acceptability, and quality of life implications of Essilor® Stellest® spectacle lenses in
 slowing myopia progression in European children and adolescents. Participants will receive
 Essilor® Stellest® at inclusion visit and will be asked for a full time wear (12 hours
 daily) for 24 months. The primary endpoints are the change in axial length and cycloplegic
 autorefraction from baseline to 24 months compared to expected change based on axial length
 and refraction centile positions at baseline.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06263946
Device Trial